SEC Filings
State Street Holds 7% Of Sarepta As The Drugmaker Faces Weaker Sales
Sarepta raised its product-revenue forecast floor by $50 million despite lower third-quarter and year-to-date sales.
Sarepta Therapeutics (SRPT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Sarepta raised its product-revenue forecast floor by $50 million despite lower third-quarter and year-to-date sales.
SEC Filings
Exon-skipping drugs lifted the sales forecast floor, while a smaller research bill helped narrow the quarterly loss.
Earnings
Sarepta will not resume the paused Envision trial; a liver-safety cohort now carries its plan for non-ambulatory Duchenne patients.